# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics t...
HC Wainwright & Co. analyst Douglas Tsao reiterates Marinus Pharma (NASDAQ:MRNS) with a Buy and maintains $11 price target.
Marinus Pharma (NASDAQ:MRNS) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0....
HC Wainwright & Co. analyst Douglas Tsao maintains Marinus Pharma (NASDAQ:MRNS) with a Buy and lowers the price target f...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...